Abstract | OBJECTIVE: METHODS: A weekly dose of 250 μg (equivalent to approximately 6,500 IU) of hCG was administered subcutaneously for 3-6 months to 56 hypogonadic oligozoospermic or severe oligozoospermic men. Semen, biochemical, and genetic analyses were performed before the start of treatment followed by analyzing semen parameters every 3 months after the start of therapy. We grouped participants into responders and non-responders depending on positive changes in semen parameters. RESULTS: Out of 56 men, 47 (83.93%) responded, while 9 (16.07%) did not. Upon statistical analysis, it was found that age did not affect the overall outcomes (p=0.292); however, men with higher body mass index (BMI; 28.09±3.48 kg/m2 ) showed better outcomes than those with low BMI (25.33±3.06 kg/m2 ) (p=0.042). The duration of therapy (in months) was higher in non-responders than in responders (p=0.020). We found significant improvements in sperm concentration (p=0.006) and count (p=0.005) after 3 months of therapy. Sperm motility and progressive motility were also found to be higher in responders, but did not show statistically significant changes. CONCLUSION:
|
Authors | Syed Waseem Andrabi, Giresh Chandra Makker, Renu Makker, Geetanjali Mishra, Rajender Singh |
Journal | Clinical and experimental reproductive medicine
(Clin Exp Reprod Med)
Vol. 49
Issue 1
Pg. 57-61
(Mar 2022)
ISSN: 2233-8233 [Print] Korea (South) |
PMID | 35255659
(Publication Type: Journal Article)
|